Related Experiment Videos
Sustained release methylphenidate: pharmacokinetic studies in ADDH males
Journal of the American Academy of Child and Adolescent Psychiatry
|September 1, 1989
Summary
This study compared methylphenidate short-acting (MPH) and long-acting (MPH-SR) formulations in children with attention deficit disorder with hyperactivity (ADDH). MPH-SR showed a longer time to peak concentration but lower peak levels than standard MPH.
Area of Science:
- Pharmacology
- Pediatric Psychiatry
Background:
- Methylphenidate is a common treatment for attention deficit disorder with hyperactivity (ADDH) in children.
- Two formulations exist: short-acting (MPH) and long-acting (MPH-SR).
Purpose of the Study:
- To compare the pharmacokinetics of MPH-SR and standard MPH in pediatric patients with ADDH.
- To evaluate differences in half-life (T 1/2), peak plasma concentrations (Cmax), and time to peak plasma concentrations (Tmax).
Main Methods:
- A pharmacokinetic study involving two groups of male children with ADDH.
- Group 1 received a single 20 mg dose of MPH-SR.
- Group 2 received a single morning dose of standard MPH.
Main Results:
- MPH-SR exhibited a longer Tmax compared to standard MPH.
- After dose adjustment, MPH-SR did not reach the same Cmax as standard MPH.
- Data on T 1/2, Cmax, and Tmax were collected for both formulations.
Conclusions:
- MPH-SR offers a prolonged release profile compared to standard MPH.
- The reduced Cmax of MPH-SR may have implications for treatment efficacy and side effect profiles.
- Further research is needed to fully elucidate the clinical significance of these pharmacokinetic differences.